SBIR Phase I: Development of Agents to Promote Cellular Ga-67 (Gallium-67) Uptake

SBIR 第一阶段：开发促进细胞 Ga-67 (Gallium-67) 吸收的药物

• 批准号: 0320485
• 负责人: Takuji Tsukamoto
• 金额: $ 10万
• 依托单位: Chemica Technologies Inc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2004-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0320485&HistoricalAwards=false
• 关键词: SBIR; Phase; Development; Agents; Promote

This Small Business Innovation Research (SBIR) Phase I project is proposes to develop new pharmaceutical agents to selectively enhance tumor imaging using gallium (Ga-67). Ga-67 has been widely used in tumor imaging and clinical medicine due to significant advantages in terms of low cost, ease of use and long life. However, the use of Ga -67 is currently limited, mainly due to varying tumor avidity and high dose requirements needed to achieve high signal-to-background ratios in non-gallium avid tumors. Increasing the selective uptake of gallium by tumor cells will dramatically improve gallium imaging, resulting in the development of an innovative, sensitive, and low-cost tumor detection tool. This Phase I program will focus on designing, preparing and evaluating novel nitrosipine derivatives with the potential to drastically increase the uptake of Ga-67 by tumor cells. The commercial application of this project is in the area of tumor imaging and oncology.

这个小型企业创新研究(SBIR)第一阶段项目建议开发新的药物制剂，使用镓(Ga-67)选择性地增强肿瘤成像。GA-67具有成本低、使用方便、使用寿命长等显著优势，已广泛应用于肿瘤影像和临床医学领域。然而，目前Ga-67的使用是有限的，主要是由于不同的肿瘤亲和力和在非嗜镓肿瘤中实现高信号背景比所需的高剂量要求。增加肿瘤细胞对镓的选择性摄取将极大地改善镓的成像，从而开发出一种创新、灵敏和低成本的肿瘤检测工具。这一第一阶段的计划将侧重于设计、制备和评估新型亚硝西平衍生物，这些衍生物具有显著增加肿瘤细胞对Ga-67摄取的潜力。该项目的商业应用是在肿瘤成像和肿瘤学领域。